Eli Lilly and Company, incorporated in 1901 in Indiana, discovers, develops, manufactures, and markets human pharmaceutical products worldwide. Operating in a single business segment, Lilly sells products in approximately 90 countries across therapeutic areas including cardiometabolic health (Mounjaro, Zepbound, Jardiance, Humalog), oncology (Verzenio, Cyramza, Retevmo, Jaypirca), immunology (Ebglyss, Olumiant), and neuroscience. The company manufactures and distributes through facilities in the U.S., Puerto Rico, Europe, and Asia.
Q2 FY2026 — expected 2026-08-11
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | LLY | discussed Automotive | |
| topic_mention | LLY | discussed Blockchain & Crypto | |
| topic_mention | LLY | discussed Semiconductor | |
| topic_mention | LLY | discussed Capital Expenditure | |
| topic_mention | LLY | discussed Regulation | |
| topic_mention | LLY | discussed Automotive | |
| topic_mention | LLY | discussed Healthcare & Bio | |
| metric | LLY total revenue | reported $45.0 billion | |
| metric | LLY gross margin | reported $83.2 percent | |
| metric | LLY gross margin | reported $82.2 percent | |
| metric | LLY gross margin | reported $38.0 percent | |
| metric | LLY gross margin | reported $81.3 percent | |
| metric | LLY gross margin | reported $28.6 percent | |
| metric | LLY gross margin | reported $47 percent | |
| metric | LLY gross margin | reported $46 percent | |
| metric | LLY EPS | reported $4.88 | |
| metric | LLY EPS | reported $11.71 | |
| guidance | LLY | guided Guidance REVENUE $45.0 billion | |
| guidance | LLY | guided FY 2024 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE: • asset impairment, restructuring and other special charges totaling $860.6 million | |
| guidance | LLY | guided FY 2023 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE: • amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0000059478-26-000013 | EDGAR | 58K words |
| 2025-02-19 | 2024-12-31 | 0000059478-25-000067 | EDGAR | 66K words |
| 2024-02-21 | 2023-12-31 | 0000059478-24-000065 | EDGAR | 67K words |
| 2023-02-22 | 2022-12-31 | 0000059478-23-000082 | EDGAR | — |
| 2022-02-23 | 2021-12-31 | 0000059478-22-000068 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0000059478-26-000081 | EDGAR | 17K words |
| 2026-04-30 | 2026-03-31 | 0000059478-26-000045 | EDGAR | 15K words |
| 2025-10-30 | 2025-09-30 | 0000059478-25-000254 | EDGAR | 23K words |
| 2025-08-07 | 2025-06-30 | 0000059478-25-000204 | EDGAR | 23K words |
| 2025-05-01 | 2025-03-31 | 0000059478-25-000132 | EDGAR | 19K words |
| 2024-10-30 | 2024-09-30 | 0000059478-24-000245 | EDGAR | 26K words |
| 2024-08-08 | 2024-06-30 | 0000059478-24-000187 | EDGAR | 25K words |
| 2024-04-30 | 2024-03-31 | 0000059478-24-000118 | EDGAR | 21K words |
| 2023-11-02 | 2023-09-30 | 0000059478-23-000284 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000059478-23-000221 | EDGAR | — |
| 2023-04-27 | 2023-03-31 | 0000059478-23-000162 | EDGAR | — |
| 2022-11-01 | 2022-09-30 | 0000059478-22-000250 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-05 | 0000059478-26-000077 | EDGAR | 6K words |
| 2026-05-20 | 0001193125-26-232707 | EDGAR | 23K words |
| 2026-05-07 | 0000059478-26-000048 | EDGAR | 1K words |
| 2026-04-30 | 0000059478-26-000043 | EDGAR | 5K words |
| 2026-02-04 | 0000059478-26-000008 | EDGAR | 6K words |
| 2025-11-21 | 0000059478-25-000271 | EDGAR | 1K words |
| 2025-10-30 | 0000059478-25-000251 | EDGAR | 6K words |
| 2025-08-20 | 0001193125-25-184093 | EDGAR | 28K words |
| 2025-08-07 | 0000059478-25-000202 | EDGAR | 6K words |
| 2025-05-08 | 0000059478-25-000138 | EDGAR | 1K words |
76 total filings indexed. 49 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| Call Date | Quarter | Title |
|---|---|---|
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript |
32 more transcripts.
Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.
| CIK | 0000059478 |
| Ticker | LLY |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | IN |
| Headquarters | Indianapolis, Indiana |
| Website | https://www.lilly.com |
| Listed | 1970-07-09 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/LLY (~200 tokens, structured JSON with cryptographic provenance)